(Q36661863)

15 August 2017

1 reference

title

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development (English)

1 reference

Carmen Escuriola Ettingshausen

15 August 2017

author

series ordinal

1

0 references

author name string

C Escuriola Ettingshausen

series ordinal

1

1 reference

15 August 2017

W Kreuz

series ordinal

2

1 reference

15 August 2017

publication date

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

12 Suppl 6

1 reference

15 August 2017

page(s)

102-106

1 reference

Inhibitors occur more frequently in African-American and Latino haemophiliacs

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

The epidemiology of inhibitors in haemophilia A: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Factor VIII immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF-beta as an immunomodulatory component in plasma-derived factor VIII concentrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

Factor VIII concentrate inhibits T helper type 2 cytokine production in vitro: relevance to inhibitor antibody formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01373.X

10.1111/J.1365-2516.2006.01373.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference